Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus

Journal of Clinical Rheumatology

Volumn 20, Issue 8, 2014, Pages 418-421

  Palavutitotai, Nattawan ^a   Buppajarntham, Tanas ^a   Katchamart, Wanruchada ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Pleural effusion; Pleuritis; Systemic lupus erythematosus; Tuberculosis

Indexed keywords

CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; COUGHING; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DYSPNEA; FEMALE; FEVER; HUMAN; LUPUS PLEURITIS; MAJOR CLINICAL STUDY; MALE; PARAPNEUMONIC EFFUSION; PERICARDITIS; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PLEURISY; PRESCRIPTION; RESPIRATORY TRACT DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; TUBERCULOUS PLEURISY; AGE DISTRIBUTION; COHORT ANALYSIS; COMPLICATION; ENDEMIC DISEASE; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NONPARAMETRIC TEST; PLEURAL EFFUSION; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SEX RATIO; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; THAILAND; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADRENAL CORTEX HORMONES; ADULT; AGE DISTRIBUTION; ANTITUBERCULAR AGENTS; COHORT STUDIES; ENDEMIC DISEASES; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLEURAL EFFUSION; PLEURISY; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THAILAND; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84916634334     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000179     Document Type: Article

References (10)

1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
2. Grigor R, Edmonds J, Lewkonia R, et al. Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis. 1978;37:121-128.
3. Jimenez S, Cervera R, Font J, et al. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003;25:3-12.
4. Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus. 2005;14:822-826.
5. Mittoo S, Gelber AC, Hitchon CA, et al. Clinical and serologic factors associated with lupus pleuritis. J Rheumatol. 2010;37:747-753.
6. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA. 1964;190: 104-111.
7. Uribe AG, Vilá LM, McGwin GJR, et al. The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2 K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004;31:1934-1940.
8. Good JT Jr, King TE, Antony VB, et al. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest. 1983;84:714-718.
9. Bouros D, Pneumatikos I. Pleural involvement in systemic autoimmune disorders. Respiration. 2008;75:361-371.
10. Toworakul C, Kasitanon N, Sukitawut W, et al. Usefulness of pleural effusion antinuclear antibodies in the diagnosis of lupus pleuritis. Lupus. 2011;20:1042-1046.